Nykode Therapeutics ASA (NYKD) - Total Assets
Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) holds total assets worth Nkr1.05 Billion NOK (≈ $111.00 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Nykode Therapeutics ASA for net asset value and shareholders' equity analysis.
Nykode Therapeutics ASA - Total Assets Trend (2016–2024)
This chart illustrates how Nykode Therapeutics ASA's total assets have evolved over time, based on quarterly financial data.
Nykode Therapeutics ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
Nykode Therapeutics ASA's total assets of Nkr1.05 Billion consist of 76.3% current assets and 23.7% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr114.82 Million | 75.2% |
| Accounts Receivable | Nkr386.00K | 0.3% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr7.74 Million | 5.0% |
| Intangible Assets | Nkr72.00K | 0.1% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Nykode Therapeutics ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NYKD company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nykode Therapeutics ASA's current assets represent 76.3% of total assets in 2024, a decrease from 99.8% in 2016.
- Cash Position: Cash and equivalents constituted 75.2% of total assets in 2024, up from 11.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is cash and equivalents at 75.2% of total assets.
Nykode Therapeutics ASA Competitors by Total Assets
Key competitors of Nykode Therapeutics ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Nykode Therapeutics ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 170.98 | 7.96 | 17.38 |
| Quick Ratio | 170.98 | 7.96 | 17.38 |
| Cash Ratio | 16.37 | 7.71 | 0.00 |
| Working Capital | Nkr663.93 Million | Nkr112.55 Million | Nkr1.85 Billion |
Nykode Therapeutics ASA - Advanced Valuation Insights
This section examines the relationship between Nykode Therapeutics ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.28 |
| Latest Market Cap to Assets Ratio | 0.72 |
| Asset Growth Rate (YoY) | -26.3% |
| Total Assets | Nkr153.48 Million |
| Market Capitalization | $110.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nykode Therapeutics ASA's assets below their book value (0.72x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Nykode Therapeutics ASA's assets decreased by 26.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nykode Therapeutics ASA (2016–2024)
The table below shows the annual total assets of Nykode Therapeutics ASA from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr153.48 Million ≈ $16.15 Million |
-26.28% |
| 2023-12-31 | Nkr208.19 Million ≈ $21.91 Million |
-6.00% |
| 2022-12-31 | Nkr221.48 Million ≈ $23.31 Million |
-16.60% |
| 2021-12-31 | Nkr265.56 Million ≈ $27.94 Million |
+15.45% |
| 2020-12-31 | Nkr230.03 Million ≈ $24.21 Million |
-21.51% |
| 2019-12-31 | Nkr293.08 Million ≈ $30.84 Million |
+91.13% |
| 2018-12-31 | Nkr153.34 Million ≈ $16.14 Million |
-28.50% |
| 2017-12-31 | Nkr214.47 Million ≈ $22.57 Million |
+760.35% |
| 2016-12-31 | Nkr24.93 Million ≈ $2.62 Million |
-- |
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more